{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:53:27Z","timestamp":1785941607181,"version":"3.56.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["JC2019013"],"award-info":[{"award-number":["JC2019013"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.arr.2023.101884","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T05:40:24Z","timestamp":1676526024000},"page":"101884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia\/reperfusion injury"],"prefix":"10.1016","volume":"86","author":[{"given":"Tiangui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.101884_bib1","unstructured":"A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Myocardial Infarction (EMPACT-MI). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674, Accessed 26th Apr 2022."},{"key":"10.1016\/j.arr.2023.101884_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-015-0258-4","article-title":"Partial inhibition of the ubiquitin-proteasome system ameliorates cardiac dysfunction following ischemia-reperfusion in the presence of high glucose","volume":"14","author":"Adams","year":"2015","journal-title":"Cardiovasc Diabetol."},{"issue":"Suppl 1","key":"10.1016\/j.arr.2023.101884_bib3","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022","volume":"45","author":"American Diabetes Association","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10787-022-00956-6","article-title":"Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK\/SIRT1 signaling and NLRP3 inflammasome","volume":"30","author":"Ammar","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.arr.2023.101884_bib5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijcard.2018.09.089","article-title":"Epicardial adipose tissue and cardiovascular diseases","volume":"278","author":"Ansaldo","year":"2019","journal-title":"Int J. Cardiol."},{"issue":"6","key":"10.1016\/j.arr.2023.101884_bib6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/biom12091195","article-title":"N-acetylcysteine, an ROS inhibitor, alleviates the pathophysiology of hyperthyroidism-induced cardiomyopathy via the ROS\/Ca2+ pathway","volume":"12","author":"Bao","year":"2022","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.arr.2023.101884_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab."},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2013.08.033","article-title":"Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe\u207b\/\u207b mice","volume":"231","author":"Burgmaier","year":"2013","journal-title":"Atherosclerosis"},{"issue":"Suppl 1","key":"10.1016\/j.arr.2023.101884_bib10","first-page":"S125","article-title":"Standards of medical care in diabetes-2021","volume":"44","author":"Cardiovascular Disease and Risk Management","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.101884_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.882181","article-title":"Association of sodium-glucose cotransporter 2 (SGLT2) inhibitor use with cardiovascular and renal outcomes in type 2 diabetes mellitus patients with stabilized acute myocardial infarction: a propensity score matching study","volume":"9","author":"Chang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.arr.2023.101884_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005146","article-title":"Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction","author":"Chen","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.arr.2023.101884_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005146","article-title":"Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction","author":"Chen","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.arr.2023.101884_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijcard.2015.12.009","article-title":"Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction","volume":"208","author":"Chen","year":"2016","journal-title":"Int J. Cardiol."},{"issue":"34","key":"10.1016\/j.arr.2023.101884_bib16","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/eurheartj\/ehy677","article-title":"Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable","volume":"40","author":"Cosentino","year":"2019","journal-title":"Eur. Heart J."},{"issue":"23","key":"10.1016\/j.arr.2023.101884_bib17","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Investigators. efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.arr.2023.101884_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.arr.2023.101884_bib19","unstructured":"Dapagliflozin Effects on Cardiovascular Events in Patients with an Acute Heart Attack (DAPA-MI). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742, Accessed 26th Apr 2022."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/dtb.2021.000073","volume":"60","author":"Dapagliflozin no longer licensed for type 1 diabetes","year":"2022","journal-title":"Drug Ther. Bull."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00395-015-0486-5","article-title":"Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling","volume":"110","author":"Das","year":"2015","journal-title":"Basic Res Cardiol."},{"issue":"24","key":"10.1016\/j.arr.2023.101884_bib22","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J. Am. Coll. Cardiol. 2018"},{"key":"10.1016\/j.arr.2023.101884_bib23","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"Das","year":"2018","journal-title":"J. Am. Coll. Cardiol. 2018"},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acsptsci.1c00207","article-title":"Canagliflozin and dapagliflozin attenuate glucolipotoxicity-induced oxidative stress and apoptosis in cardiomyocytes via inhibition of sodium-glucose cotransporter-1","volume":"5","author":"Dasari","year":"2022","journal-title":"ACS Pharm. Transl. Sci."},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.arr.2023.101884_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015748","article-title":"B7-33, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice","volume":"9","author":"Devarakonda","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.arr.2023.101884_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2925","article-title":"Liraglutide mitigates TNF-\u03b1 induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women","volume":"33","author":"Di Tomo","year":"2017","journal-title":"Diabetes Metab. Res Rev."},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40256-018-0275-2","article-title":"A systematic review on the protective effect of N-acetyl cysteine against diabetes-associated cardiovascular complications","volume":"18","author":"Dludla","year":"2018","journal-title":"Am. J. Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12265-020-09984-5","article-title":"Exendin-4 protects against myocardial ischemia-reperfusion injury by upregulation of SIRT1 and SIRT3 and activation of AMPK","volume":"14","author":"Eid","year":"2021","journal-title":"J. Cardiovasc Transl. Res"},{"issue":"6","key":"10.1016\/j.arr.2023.101884_bib31","doi-asserted-by":"crossref","first-page":"14670","DOI":"10.1080\/21655979.2022.2066748","article-title":"Nesfatin-1 protects against diabetic cardiomyopathy in the streptozotocin-induced diabetic mouse model via the p38-MAPK pathway","volume":"13","author":"Fan","year":"2022","journal-title":"Bioengineered"},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/a-1240-4936","article-title":"Glucagon like peptide-1 receptor agonists alter pancreatic and hepatic histology and regulation of endoplasmic reticulum stress in high-fat diet mouse model","volume":"129","author":"Fang","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"7","key":"10.1016\/j.arr.2023.101884_bib33","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"Protection in the EMPA-REG outcome trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.arr.2023.101884_bib34","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"issue":"10193","key":"10.1016\/j.arr.2023.101884_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"39","key":"10.1016\/j.arr.2023.101884_bib37","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","volume":"40","author":"Grant","year":"2019","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -\/- mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1074248412468945","article-title":"Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart","volume":"18","author":"Hausenloy","year":"2013","journal-title":"J. Cardiovasc Pharm. Ther."},{"issue":"7","key":"10.1016\/j.arr.2023.101884_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/cvr\/cvz053","article-title":"Cardiac innervation in acute myocardial ischaemia\/reperfusion injury and cardioprotection","volume":"115","author":"Hausenloy","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.arr.2023.101884_bib41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"10157","key":"10.1016\/j.arr.2023.101884_bib42","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cardfail.2021.07.022","article-title":"Effect of empagliflozin versus placebo on body fluid balance in patients with acute myocardial infarction and type 2 diabetes mellitus: subgroup analysis of the EMBODY trial","volume":"28","author":"Hoshika","year":"2022","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.arr.2023.101884_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8836904","article-title":"The role of oxymatrine in amelioration of acute lung injury subjected to myocardial I\/R by inhibiting endoplasmic reticulum stress in diabetic rats","volume":"2020","author":"Huang","year":"2020","journal-title":"Evid. Based Complement Altern. Med"},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.arr.2023.101884_bib46","doi-asserted-by":"crossref","unstructured":"acobellis G., Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. Obesity (Silver Spring). 2020;28(6):1068\u20131074. doi: 10.1002\/oby.22798. PMID: 32352644.","DOI":"10.1002\/oby.22798"},{"issue":"14","key":"10.1016\/j.arr.2023.101884_bib47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1161\/CIRCULATIONAHA.113.003653","volume":"128","author":"Ibanez","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21020","article-title":"Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation","volume":"21","author":"Johnston","year":"2017","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.arr.2023.101884_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172620","article-title":"Novel repair mechanisms in a renal ischaemia\/reperfusion model: subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1\/cAMP\/VEGF, ANP\/eNOS\/NO, SDF-1\u03b1\/CXCR4, and Kim-1\/STAT3\/HIF-1\u03b1\/VEGF\/eNOS pathways","volume":"861","author":"Kamel","year":"2019","journal-title":"Eur. J. Pharm."},{"issue":"8","key":"10.1016\/j.arr.2023.101884_bib50","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-11-0098","article-title":"Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction","volume":"75","author":"Kataoka","year":"2011","journal-title":"Circ. J."},{"issue":"18","key":"10.1016\/j.arr.2023.101884_bib51","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jacc.2022.02.046","article-title":"Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison","volume":"79","author":"Kelsey","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.amjcard.2009.10.048","article-title":"Reach Registry Investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)","volume":"105","author":"Krempf","year":"2010","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.arr.2023.101884_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-019-0872-7","article-title":"Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes","volume":"18","author":"Kristiansen","year":"2019","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib55","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther."},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib56","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1080\/13880209.2020.1840597","article-title":"Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1\u03b1\/NF-\u03baB\/IL-6 pathway","volume":"58","author":"Lai","year":"2020","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.arr.2023.101884_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yjmcc.2015.12.020","article-title":"Ischemia\/reperfusion injury, ischemic conditioning and diabetes mellitus","volume":"91","author":"Lejay","year":"2016","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.arr.2023.101884_bib58","article-title":"ZP2495 protects against myocardial ischemia\/reperfusion injury in diabetic mice through improvement of cardiac metabolism and mitochondrial function: the possible involvement of AMPK-FoxO3a signal pathway","volume":"2018","author":"Li","year":"2018","journal-title":"Oxid. Med Cell Longev."},{"issue":"11","key":"10.1016\/j.arr.2023.101884_bib59","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms22116044","article-title":"Sodium glucose Co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.arr.2023.101884_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11886-018-1051-2","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect?","volume":"20","author":"Li","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib61","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/CIRCULATIONAHA.118.039262","article-title":"S100a8\/a9 signaling causes mitochondrial dysfunction and cardiomyocyte death in response to ischemic\/reperfusion injury","volume":"140","author":"Li","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.arr.2023.101884_bib62","article-title":"A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.arr.2023.101884_bib63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"L\u00f8nborg","year":"2012","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib64","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/jcmm.13451","article-title":"Mammalian target of rapamycin inhibition attenuates myocardial ischaemia-reperfusion injury in hypertrophic heart","volume":"22","author":"Ma","year":"2018","journal-title":"J. Cell Mol. Med"},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib65","first-page":"891","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER trial investigators. liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"7","key":"10.1016\/j.arr.2023.101884_bib67","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/jcm11071904","article-title":"The impact of novel anti-diabetic medications on CV outcomes: a new therapeutic horizon for diabetic and non-diabetic cardiac patients","volume":"11","author":"Mazin","year":"2022","journal-title":"J. Clin. Med"},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcin.2014.09.014","article-title":"Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization","volume":"8","author":"McCormick","year":"2015","journal-title":"JACC Cardiovasc Inter."},{"key":"10.1016\/j.arr.2023.101884_bib69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-015-0259-3","article-title":"Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus","volume":"14","author":"McCormick","year":"2015","journal-title":"Cardiovasc Diabetol."},{"issue":"21","key":"10.1016\/j.arr.2023.101884_bib70","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.arr.2023.101884_bib71","doi-asserted-by":"crossref","unstructured":"Mohammed El Tabaa M, Mohammed El Tabaa M, Anis A, Mohamed Elgharabawy R, Borai El-Borai N. GLP-1 mediates the neuroprotective action of crocin against cigarette smoking-induced cognitive disorders via suppressing HMGB1-RAGE\/TLR4-NF-\u03baB pathway. Int Immunopharmacol. 2022; 110: 108995. doi: 10.1016\/j.intimp.2022.108995. PMID: 35785730.","DOI":"10.1016\/j.intimp.2022.108995"},{"issue":"16","key":"10.1016\/j.arr.2023.101884_bib72","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/eurheartj\/ehv592","article-title":"Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments","volume":"37","author":"Montecucco","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.arr.2023.101884_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopha.2018.03.047","article-title":"Anti-arrhythmogenic and anti-inflammatory effects of troxerutin in ischemia\/reperfusion injury of diabetic myocardium","volume":"102","author":"Najafi","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib74","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","article-title":"Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence","volume":"20","author":"Natali","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arr.2023.101884_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154031","article-title":"The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship","volume":"103","author":"Nauck","year":"2020","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1479164118783935","article-title":"LEADER Publication Committee on behalf of the LEADER Trial Investigators. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial","volume":"15","author":"Nauck","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"issue":"Suppl 3","key":"10.1016\/j.arr.2023.101884_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.101884_bib78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"7","key":"10.1016\/j.arr.2023.101884_bib79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.arr.2023.101884_bib80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"18","key":"10.1016\/j.arr.2023.101884_bib81","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.arr.2023.101884_bib82","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib83","doi-asserted-by":"crossref","first-page":"889","DOI":"10.33549\/physiolres.933558","article-title":"Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress","volume":"66","author":"Palee","year":"2017","journal-title":"Physiol. Res"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arr.2023.101884_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.647785","article-title":"Post-ischemic myocardial inflammatory response: a complex and dynamic process susceptible to immunomodulatory therapies","volume":"8","author":"Pluijmert","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.arr.2023.101884_bib86","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fphys.2018.00579","article-title":"Diabetes worsens skeletal muscle mitochondrial function, oxidative stress, and apoptosis after lower-limb ischemia-reperfusion: implication of the RISK and SAFE pathways?","volume":"9","author":"Pottecher","year":"2018","journal-title":"Front. Physiol."},{"issue":"11","key":"10.1016\/j.arr.2023.101884_bib87","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/dom.13488","article-title":"Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?","volume":"20","author":"Prattichizzo","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.101884_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8151836","article-title":"Aggravates high glucose- and hypoxia\/reoxygenation-induced injury through activating ros-dependent nlrp3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes","volume":"2019","author":"Qiu","year":"2019","journal-title":"J. Diabetes Res"},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib89","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FJC.0b013e3181d26583","article-title":"Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase\/Akt and endothelial nitric oxide synthase signaling","volume":"55","author":"Raphael","year":"2010","journal-title":"J. Cardiovasc Pharm."},{"issue":"15","key":"10.1016\/j.arr.2023.101884_bib90","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib91","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2337\/dc19-0950","article-title":"Within-trial evaluation of medical resources, costs, and quality of life among patients with type 2 diabetes participating in the exenatide study of cardiovascular event lowering (EXSCEL)","volume":"43","author":"Reed","year":"2020","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.arr.2023.101884_bib92","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/dom.13002","article-title":"Relationship between diabetes and ischaemic injury among patients with revascularized ST-elevation myocardial infarction","volume":"19","author":"Reinstadler","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.arr.2023.101884_bib93","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ. Res"},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib94","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","volume":"39","author":"Schmidt","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.arr.2023.101884_bib95","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1745-6215-12-240","article-title":"Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial","volume":"12","author":"Scholte","year":"2011","journal-title":"Trials"},{"issue":"8","key":"10.1016\/j.arr.2023.101884_bib96","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2337\/dc18-0158","article-title":"Free fatty acids, and cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome","volume":"41","author":"Schrieks","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib97","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.arr.2023.101884_bib98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-010-0500-z","article-title":"Involvement of GSK-3\u03b2 in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart","volume":"343","author":"Singh, M","year":"2010","journal-title":"Mol. Cell Biochem."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib99","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cns.13791","article-title":"Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway","volume":"28","author":"Song","year":"2022","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","article-title":"Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events","volume":"19","author":"Spigoni","year":"2020","journal-title":"Cardiovasc Diabetol."},{"issue":"13","key":"10.1016\/j.arr.2023.101884_bib101","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCULATIONAHA.119.043833","article-title":"Neutrophil-derived S100A8\/A9 amplify granulopoiesis after myocardial infarction","volume":"141","author":"Sreejit","year":"2020","journal-title":"Circulation"},{"issue":"1S","key":"10.1016\/j.arr.2023.101884_bib102","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2017.05.013","article-title":"Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms","volume":"120","author":"Staels","year":"2017","journal-title":"Am. J. Cardiol."},{"issue":"10","key":"10.1016\/j.arr.2023.101884_bib103","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3390\/life12101663","article-title":"Oxidative stress management in cardiorenal diseases: focus on novel antidiabetic agents, finerenone, and melatonin","volume":"12","author":"Theofilis","year":"2022","journal-title":"Life"},{"issue":"6","key":"10.1016\/j.arr.2023.101884_bib104","doi-asserted-by":"crossref","first-page":"H1553","DOI":"10.1152\/ajpheart.00158.2018","article-title":"Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury","volume":"315","author":"Toldo","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvaa004","article-title":"Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction","volume":"7","author":"Trevisan","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharm."},{"key":"10.1016\/j.arr.2023.101884_bib106","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2019.12.004","article-title":"Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial (NCT03087773)","volume":"221","author":"Tripolt","year":"2020","journal-title":"Am. Heart J."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib107","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib108","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol. Biochem"},{"key":"10.1016\/j.arr.2023.101884_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.arr.2023.101884_bib110","first-page":"609","article-title":"Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism","volume":"113","author":"Valle Raleigh","year":"2017","journal-title":"Cardiovasc Res."},{"key":"10.1016\/j.arr.2023.101884_bib111","article-title":"A case of Fournier's gangrene following a large-volume hydrocelectomy in a diabetic patient managed with SGLT-2 inhibitor therapy","volume":"39","author":"Vargo","year":"2021","journal-title":"Urol. Case Rep."},{"key":"10.1016\/j.arr.2023.101884_bib112","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib113","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12933-020-01188-0","article-title":"Impact of peroxisome proliferator-activated receptor-\u03b1 on diabetic cardiomyopathy","volume":"20","author":"Wang","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.arr.2023.101884_bib115","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9257291","article-title":"N-acetylcysteine attenuates diabetic myocardial ischemia reperfusion injury through inhibiting excessive autophagy","volume":"2017","author":"Wang","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.arr.2023.101884_bib116","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.freeradbiomed.2013.05.043","article-title":"N-Acetylcysteine and allopurinol up-regulated the Jak\/STAT3 and PI3K\/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes","volume":"63","author":"Wang","year":"2013","journal-title":"Free Radic. Biol. Med"},{"issue":"4","key":"10.1016\/j.arr.2023.101884_bib117","first-page":"2441","article-title":"Effects of propofol on LC3II and mTOR\/p-mTOR expression during ischemia-reperfusion myocardium injury in rats with type 2 diabetes mellitus","volume":"19","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.arr.2023.101884_bib118","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.taap.2018.08.023","article-title":"GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic\/reperfusional injury in mice","volume":"357","author":"Wang","year":"2018","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.arr.2023.101884_bib119","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.arr.2023.101884_bib120","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","article-title":"Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study","volume":"33","author":"Woo","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.arr.2023.101884_bib121","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14740338.2018.1424826","article-title":"The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Wu","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"13","key":"10.1016\/j.arr.2023.101884_bib123","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.3390\/ijms22137170","article-title":"Impact of sodium-glucose co-transporter 2 inhibitors on cardiac protection","volume":"22","author":"Wu","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.101884_bib124","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6614009","article-title":"Role of oxidative stress in reperfusion following myocardial ischemia and its treatments","volume":"2021","author":"Xiang","year":"2021","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.arr.2023.101884_bib125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.arr.2023.101884_bib126","first-page":"1253","article-title":"Cardioprotective effects of anisodamine against myocardial ischemia\/reperfusion injury through the inhibition of oxidative stress, inflammation and apoptosis","volume":"17","author":"Yao","year":"2018","journal-title":"Mol. Med Rep."},{"issue":"3","key":"10.1016\/j.arr.2023.101884_bib127","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNR.0000000000001190","article-title":"Metformin reduces neuronal damage and promotes neuroblast proliferation and differentiation in a cerebral ischemia\/reperfusion rat model","volume":"30","author":"Yuan","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.arr.2023.101884_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.101884_bib129","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbrc.2021.02.065","article-title":"Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice","volume":"548","author":"Zhang","year":"2021","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.arr.2023.101884_bib130","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1155\/2017\/6437467","article-title":"Insights for oxidative stress and mTOR signaling in myocardial ischemia\/reperfusion injury under diabetes","volume":"2017","author":"Zhao","year":"2017","journal-title":"Oxid. Med Cell Longev."},{"issue":"2","key":"10.1016\/j.arr.2023.101884_bib131","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.101884_bib132","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG outcome investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl. J. Med"},{"issue":"11","key":"10.1016\/j.arr.2023.101884_bib133","first-page":"1094","article-title":"Cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"New Engl. J. Med"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:05:21Z","timestamp":1761591921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":133,"alternative-id":["S1568163723000430"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.101884","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia\/reperfusion injury","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.101884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101884"}}